A translational pharmacology approach to understanding the predictive value of abuse potential assessments

Behavioural Pharmacology

Volumn 24, Issue 5-6, 2013, Pages 410-436

  Horton, David B ^a   Potter, David M ^a   Mead, Andy N ^a  

^a PFIZER INC   (United States)

Author keywords

abuse liability; abuse potential; drug discovery; human; predictive value; rat; safety; scheduling; translation

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; AMOBARBITAL; AMPHETAMINE; CATHINONE; COCAINE; CODEINE; DEXTROPROPOXYPHENE; DIAMORPHINE; DIHYDROETORPHINE; ETONITAZENE; FENTANYL; HEXOBARBITAL; HYDROCODONE; KETAMINE; LEVACETYLMETHADOL; MESCALINE; METHADONE; METHAMPHETAMINE; METHYLPHENIDATE; NALORPHINE; OXYCODONE; PENTOBARBITAL; PETHIDINE; PHENCYCLIDINE; PHENMETRAZINE; REMIFENTANIL; SUFENTANIL; UNINDEXED DRUG;

BINDING AFFINITY; DECISION MAKING; DRUG ABUSE; DRUG DEPENDENCE; DRUG DISCRIMINATION; DRUG INDUSTRY; DRUG RECEPTOR BINDING; DRUG SELF ADMINISTRATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; NONHUMAN; PREDICTIVE VALUE; PUBLIC HEALTH; REVIEW; SOCIAL ASPECT; SOCIOECONOMICS;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DATABASES, FACTUAL; DRUG INDUSTRY; HUMANS; MOTOR ACTIVITY; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84881542259     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283644d2e     Document Type: Review

References (373)

1. Addy C, Jumes P, Rosko K, Li S, Li H, Maes A, et al. (2009). Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist. J Clin Pharmacol 49:1228-1238
2. Appel JB, West WB, Rolandi WG, Alici T, Pechersky K (1999). Increasing the selectivity of drug discrimination procedures. Pharmacol Biochem Behav 64:353-358
3. Arfken CL, Schuster CR, Johanson CE (2003). Postmarketing surveillance of abuse liability of sibutramine. Drug Alcohol Depend 69:169-173
4. Arias HR, Santamaria A, Ali SF (2009). Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol 88:223-255
5. Arnt J (1989). Characterization of the discriminative stimulus properties induced by 5-HT1 and 5-HT2 agonists in rats. Pharmacol Toxicol 64: 165-172
6. Arnt J (1995). Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-Amphetamine. Eur J Pharmacol 283:55-62
7. Ashton H, Young AH (2003). GABA-ergic drugs: Exit stage left, enter stage right. J Psychopharmacol 17:174-178
8. Atack JR (2005). The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Expert Opin Investig Drugs 14:601-618
9. Atkinson J, Enslen M (1976). Self-Administration of caffeine by the rat. Arzneimittelforschung 26:2059-2061
10. Ator NA, Griffiths RR (1989). Differential generalization to pentobarbital in rats trained to discriminate lorazepam, chlordiazepoxide, diazepam, or triazolam. Psychopharmacology (Berl) 98:20-30
11. Ator NA, Griffiths RR (2003). Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend 70:S55-S72
12. Aulakh CS, Hill JL, Wozniak KM, Murphy DL (1988). Fenfluramine-induced suppression of food intake and locomotor activity is differentially altered by the selective type A monoamine oxidase inhibitor clorgyline. Psychopharmacology (Berl) 95:313-317
13. Awasaki Y, Nishida N, Sasaki S, Sato S (1997). Dopamine D(1) antagonist SCH23390 attenuates self-Administration of both cocaine and fentanyl in rats. Environ Toxicol Pharmacol 3:115-122
14. Baker GB, Coutts RT, McKenna KF, Sherry-McKenna RL (1992). Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: A review. J Psychiatry Neurosci 17:206-214
15. Ballard ME, Basso AM, Gallagher KB, Browman KE, Fox GB, Drescher KU, et al. (2007). The drug-induced helplessness test: An animal assay for assessing behavioral despair in response to neuroleptic treatment. Psychopharmacology (Berl) 190:1-11
16. Barrett RL,Wiley JL, Balster RL, Martin BR (1995). Pharmacological specificity of delta 9-Tetrahydrocannabinol discrimination in rats. Psychopharmacology (Berl) 118:419-424
17. Bartoletti M, Gaiardi M, Gubellini C, Babbini M (1983). Further evidence for a motility substitution test as a tool to detect the narcotic character of new drugs in rats. Neuropharmacology 22:177-181
18. Bartoletti M, Gaiardi M, Gubellini C, Bacchi A, Babbini M (1989). Timedependent generalization of morphine stimulus properties to meperidine: Antagonism by naloxone. Pharmacol Biochem Behav 34:429-431
19. Baumann P (1996). Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol 11 (Suppl 1):5-11
20. Baylon GJ, Kaplan HL, Somer G, Busto UE, Sellers EM (2000). Comparative abuse liability of intravenously administered remifentanil and fentanyl. J Clin Psychopharmacol 20:597-606
21. Beardsley PM, Harris LS (1997). Evaluation of the discriminative stimulus and reinforcing effects of dihydroetorphine. Drug Alcohol Depend 48: 77-84
22. Beardsley PM, Aceto MD, Cook CD, Bowman ER, Newman JL, Harris LS (2004). Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys. Exp Clin Psychopharmacol 12:163-172
23. Beaugrand J St, Laurent J (1973). Effects of D-methyl-p-Tyrosine and L-DOPA on brain self-stimulation and motor activity in rats. Br J Pharmacol 47: 609-612
24. Bechelli LP, Navas F, Pierangelo SA (1982). Comparison of the reinforcing properties of zopiclone and triazolam in former alcoholics. Int Pharmacopsychiatry 17 (Suppl 2):235-241
25. Bedford JA, Borne RF, Wilson MC (1980). Comparative behavioral profile of cocaine and norcocaine in rats and monkeys. Pharmacol Biochem Behav 13:69-75
26. Bednarczyk B, Vetulani J (1977). Stimulatory and inhibitory action of clonidine on the locomotor activity in the rat. Pol J Pharmacol Pharm 29:219-229
27. Bergman J (2008). Medications for stimulant abuse: Agonist-based strategies and preclinical evaluation of the mixed-Action D-sub-2 partial agonist aripiprazole (Abilify). Exp Clin Psychopharmacol 16:475-483
28. Bergman SA (1999). Ketamine: Review of its pharmacology and its use in pediatric anesthesia. Anesth Prog 46:10-20
29. Bexis S, Docherty JR (2006). Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve alpha-Adrenoceptors. Br J Pharmacol 147:926-934
30. Bjork JM, Gaytan O, Patt N, Swann AC, Dafny N (1998). Behavioral tolerance to and withdrawal from multiple fluoxetine administration. Int J Neurosci 93:163-179
31. Bispo Da Silva LB, Cordellini S (2003). Effects of diethylpropion treatment and withdrawal on aorta reactivity, endothelial factors and rat behavior. Toxicol Appl Pharmacol 190:170-176
32. Botly LC, Burton CL, Rizos Z, Fletcher PJ (2008). Characterization of methylphenidate self-Administration and reinstatement in the rat. Psychopharmacology (Berl) 199:55-66
33. Brady KT, Balster RL (1982). Discriminative stimulus properties of ketamine stereoisomers in phencyclidine-Trained rats. Pharmacol Biochem Behav 17:291-295
34. Brauer LH, Johanson CE, Schuster CR, Rothman RB, de Wit H (1996). Evaluation of phentermine and fenfluramine, alone and in combination, in normal, healthy volunteers. Neuropsychopharmacology 14:233-241
35. Breese GR, Cooper BR, Hollister AS (1975). Involvement of brain monoamines in the stimulant and paradoxical inhibitory effects of methylphenidate. Psychopharmacologia 44:5-10
36. Brenneisen R, Fisch HU, Koelbing U, Geisshusler S, Kalix P (1990). Amphetamine-Like effects in humans of the khat alkaloid cathinone. Br J Clin Pharmacol 30:825-828
37. Briscoe RJ, Vanecek SA, Vallett M, Baird TJ, Holloway FA, Gauvin DV (1998). Reinforcing effects of caffeine, ephedrine, and their binary combination in rats. Pharmacol Biochem Behav 60:685-693
38. Broadbent J, Gaspard TM, Dworkin SI (1995). Assessment of the discriminative stimulus effects of cocaine in the rat: Lack of interaction with opioids. Pharmacol Biochem Behav 51:379-385
39. Browne RG, Segal DS (1980). Behavioral activating effects of opiates and opioid peptides. Biol Psychiatry 15:77-86
40. Bryan-Lluka LJ, Siebert GA, Pond SM (1999). Potencies of haloperidol metabolites as inhibitors of the human noradrenaline, dopamine and serotonin transporters in transfected COS-7 cells. Naunyn Schmiedebergs Arch Pharmacol 360:109-115
41. Bueno OF, Carlini EA, Finkelfarb E, Suzuki JS (1976). Delta 9-Tetrahydrocannabinol, ethanol, and amphetamine as discriminative stimuli-generalization tests with other drugs. Psychopharmacologia 46:235-243
42. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, et al. (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711
43. Callahan PM, Cunningham KA (1993). Discriminative stimulus properties of cocaine in relation to dopamine D2 receptor function in rats. J Pharmacol Exp Ther 266:585-592
44. Cami J, Farre M, Mas M, Roset PN, Poudevida S, Mas A, et al. (2000). Human pharmacology of 3,4-methylenedioxymethamphetamine ('ecstasy'): Psychomotor performance and subjective effects. J Clin Psychopharmacol 20:455-466
45. Canning H, Goff D, Leach MJ, Miller AA, Tateson JE, Wheatley PL (1979). The involvement of dopamine in the central actions of bupropion, a new antidepressant [proceedings]. Br J Pharmacol 66:104P-105P.
46. Carroll ME, France CP, Meisch RA (1981). Intravenous self-Administration of etonitazene, cocaine and phencyclidine in rats during food deprivation and satiation. J Pharmacol Exp Ther 217:241-247
47. Carroll ME, Boe IN (1982). Increased intravenous drug self-Administration during deprivation of other reinforcers. Pharmacol Biochem Behav 17:563-567
48. Carter LP, Unzeitig AW,Wu H, ChenW, Coop A, KoekW, France CP (2004). The discriminative stimulus effects of gamma-hydroxybutyrate and related compounds in rats discriminating baclofen or diazepam: The role of GABA(B) and GABA(A) receptors. J Pharmacol Exp Ther 309:540-547
49. Carter LP, Richards BD, Mintzer MZ, Griffiths RR (2006). Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacology 31:2537-2551
50. Carter LP, Griffiths RR (2009a). Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend 105:S14-S25
51. Carter LP, Griffiths RR (2009b). Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend 105 (Suppl 1):S14-S25
52. Castellani S, Adams PM (1981). Acute and chronic phencyclidine effects on locomotor activity, stereotypy and ataxia in rats. Eur J Pharmacol 73: 143-154
53. Chait LD, Uhlenhuth EH, Johanson CE (1987). Reinforcing and subjective effects of several anorectics in normal human volunteers. J Pharmacol Exp Ther 242:777-783
54. Chait LD (1994). Factors influencing the reinforcing and subjective effects of ephedrine in humans. Psychopharmacology (Berl) 113:381-387
55. Chen L, Yang CR (2002). Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J Neurophysiol 87:2324-2336
56. Childs E, de Wit H (2006). Subjective, behavioral, and physiological effects of acute caffeine in light, nondependent caffeine users. Psychopharmacology (Berl) 185:514-523
57. Clarke PB, Kumar R (1983). The effects of nicotine on locomotor activity in nontolerant and tolerant rats. Br J Pharmacol 78:329-337
58. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al. (2005). Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48:3474-3477
59. Collins RJ, Weeks JR, Cooper MM, Good PI, Russell RR (1984). Prediction of abuse liability of drugs using IV self-Administration by rats. Psychopharmacology (Berl) 82:6-13
60. Colombo G, Agabio R, Balaklievskaia N, Diaz G, Lobina C, Reali R, Gessa GL (1995). Oral self-Administration of gamma-hydroxybutyric acid in the rat. Eur J Pharmacol 285:103-107
61. Colpaert FC, Janssen PA (1984). Agonist and antagonist effects of prototype opiate drugs in rats discriminating fentanyl from saline: Characteristics of partial generalization. J Pharmacol Exp Ther 230:193-199
62. Colpaert FC, Niemegeers CJ, Janssen PA (1976a). On the ability of narcotic antagonists to produce the narcotic cue. J Pharmacol Exp Ther 197: 180-187
63. Colpaert FC, Kuyps JJ, Niemegeers CJ, Janssen PA (1976b). Discriminative stimulus properties of fentanyl and morphine: Tolerance and dependence. Pharmacol Biochem Behav 5:401-408
64. Comer SD, Collins ED, Wilson ST, Donovan MR, Foltin RW, Fischman MW (1998). Effects of an alternative reinforcer on intravenous heroin selfadministration by humans. Eur J Pharmacol 345:13-26
65. Cone EJ, Welch P, Lange WR (1988). Clonidine partially blocks the physiologic effects but not the subjective effects produced by smoking marijuana in male human subjects. Pharmacol Biochem Behav 29:649-652
66. Cooper BR, Hester TJ, Maxwell RA (1980). Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): Evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 215:127-134
67. Corrigall WA, Coen KM (1989). Nicotine maintains robust self-Administration in rats on a limited-Access schedule. Psychopharmacology (Berl) 99:473-478
68. Costa E, Naimzada KM, Revuelta A (1971). Effect of phenmetrazine, aminorex and p-chloramphetamine on the motor activity and turnover rate of brain catecholamines. Br J Pharmacol 43:570-579
69. Cott J, Carlsson A, Engel J, Lindqvist M (1976). Suppression of ethanol-induced locomotor stimulation by GABA-Like drugs. Naunyn Schmiedebergs Arch Pharmacol 295:203-209
70. Coulthard MG (2007). Quantifying how tests reduce diagnostic uncertainty. Arch Dis Child 92:404-408
71. Craft RM, Bernal SA (2001). Sex differences in opioid antinociception: Kappa and 'mixed action' agonists. Drug Alcohol Depend 63:215-228
72. Craft RM, McNiel DM (2003). Agonist/antagonist properties of nalbuphine, butorphanol and (-)-pentazocine in male vs. female rats. Pharmacol Biochem Behav 75:235-245
73. Creese I, Iversen SD (1975). The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Res 83:419-436
74. Crestani F, Martin JR, Mohler H, Rudolph U (2000). Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 131:1251-1254
75. Croxtall JD (2012). Aripiprazole: A review of its use in the management of schizophrenia in adults. CNS Drugs 26:155-183
76. Cruickshank CC, Dyer KR (2009). A review of the clinical pharmacology of methamphetamine. Addiction 104:1085-1099
77. Curran MA, Newman LM, Becker GL (1988). Barbiturate anesthesia and alcohol tolerance in a rat model. Anesth Analg 67:868-871
78. Czachowski CL, Samson HH (1999). Breakpoint determination and ethanol selfadministration using an across-session progressive ratio procedure in the rat. Alcohol Clin Exp Res 23:1580-1586
79. D'Mello GD, Stolerman IP (1977). Comparison of the discriminative stimulus properties of cocaine and amphetamine in rats. Br J Pharmacol 61: 415-422
80. Davies MF, Onaivi ES, Chen SW, Maguire PA, Tsai NF, Loew GH (1994). Evidence for central benzodiazepine receptor heterogeneity from behavior tests. Pharmacol Biochem Behav 49:47-56
81. Davis JD, Lulenski GC, Miller NE (1968). Comparative studies of barbiturate selfAdministration. Int J Addict 3:207-214
82. Davis WM, Smith TE, Smith SG (1987). Intravenous and intragastric selfadministration of chlordiazepoxide in the rat. Alcohol Drug Res 7:511-516
83. Davis WM, Smith SG, Werner TE, Braude MC (1977). Intragastric selfadministration of hallucinogens in the rat In: Federation of American Societies for Experimental Biology: 61st Annual Meeting, 1-8 April 1977; Chicago, IL, USA
84. De Vry J, Koek W, Slangen JL (1984). Effects of drug-induced differences in reinforcement frequency on discriminative stimulus properties of fentanyl. Psychopharmacology (Berl) 83:257-261
85. DeWit H, Uhlenhuth EH, Johanson CE (1984). Lack of preference for flurazepam in normal volunteers. Pharmacol Biochem Behav 21:865-869
86. Deroche-Gamonet V, Darnaudery M, Bruins-Slot L, Piat F, Le Moal M, Piazza PV (2002). Study of the addictive potential of modafinil in naive and cocaineexperienced rats. Psychopharmacology (Berl) 161:387-395
87. Desai RI, Barber DJ, Terry P (1999). Asymmetric generalization between the discriminative stimulus effects of nicotine and cocaine. Behav Pharmacol 10:647-656
88. Desai RI, Bergman J (2010). Drug discrimination in methamphetamine- Trained rats: Effects of cholinergic nicotinic compounds. J Pharmacol Exp Ther 335:807-816
89. Dharmshaktu P, Tayal V, Kalra BS (2012). Efficacy of antidepressants as analgesics: A review. J Clin Pharmacol 52:6-17
90. Donny EC, Caggiula AR, Mielke MM, Booth S, Gharib MA, Hoffman A, et al. (1999). Nicotine self-Administration in rats on a progressive ratio schedule of reinforcement. Psychopharmacology (Berl) 147:135-142
91. Eissenberg T, Stitzer ML, Bigelow GE, Buchhalter AR,Walsh SL (1999). Relative potency of levo-Alpha-Acetylmethadol and methadone in humans under acute dosing conditions. J Pharmacol Exp Ther 289:936-945
92. EMA (2006). Guideline on the non-clinical investigation of the dependence potential of medicinal products. Available at: Http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2009/09/ WC500003360.pdf. [Accessed 14 June 2013
93. Engberg G, Elebring T, Nissbrandt H (1991). Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. J Pharmacol Exp Ther 259:841-847
94. Errick JK, Heel RC (1983). Nalbuphine. A preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 26:191-211
95. Fauman BJ, Fauman MA (1980). Chronic phenycyclidine (PCP) abuse: A psychiatric perspective-part II: Psychosis [proceedings]. Psychopharmacol Bull 16:72-73
96. FDA-CDER (2010). Guidance for industry: Assessment of abuse potential of drugs (draft guidance). Available at: Http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM198650.pdf. [Accessed 14 June 2013
97. Fennessy MR, Laska FJ (1979). Acute effects of opiate agonists, partial agonists and antagonists on brain monoamines in the rat. Arch Int Pharmacodyn Ther 238:60-70
98. Fidecka S, Malec D, Langwinski R (1978). Central action of narcotic analgesics. II. Locomotor activity and narcotic analgesics. Pol J Pharmacol Pharm 30: 5-16
99. File SE (1981). Rapid development of tolerance to the sedative effects of lorazepam and triazolam in rats. Psychopharmacology (Berl) 73: 240-245
100. File SE (1983). Variability in behavioral responses to benzodiazepines in the rat. Pharmacol Biochem Behav 18:303-306
101. Filip M, Frankowska M, Golda A, Zaniewska M, Vetulani J, Przegalinski E (2006). Various GABA-mimetic drugs differently affect cocaine-evoked hyperlocomotion and sensitization. Eur J Pharmacol 541:163-170
102. Filip M, Frankowska M, Zaniewska M, Golda A, Przegalinski E, Vetulani J (2007). Diverse effects of GABA-mimetic drugs on cocaine-evoked self-Administration and discriminative stimulus effects in rats. Psychopharmacology (Berl) 192:17-26
103. Fingerhood MI, Sullivan JT, Testa M, Jasinski DR (1997). Abuse liability of testosterone. J Psychopharmacol 11:59-63
104. Fink H, Morgenstern R (1980). Scopolamine-induced hypermotility in rats is mediated via a dopaminergic system. Acta Biol Med Ger 39:903-910
105. Fischman MW (1989). Relationship between self-reported drug effects and their reinforcing effects: Studies with stimulant drugs. NIDA Res Monogr 92: 211-230
106. Fischman MW, Foltin RW (1991). Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict 86: 1563-1570
107. Fletcher PJ, Sinyard J, Higgins GA (2006). The effects of the 5-HT(2C) receptor antagonist SB242084 on locomotor activity induced by selective, or mixed, indirect serotonergic and dopaminergic agonists. Psychopharmacology (Berl) 187:515-525
108. Foltin RW, Fischman MW (1991). Assessment of abuse liability of stimulant drugs in humans: A methodological survey. Drug Alcohol Depend 28:3-48
109. French ED, Lopez M, Peper S, Kamenka JM, Roberts DC (1995). A comparison of the reinforcing efficacy of PCP, the PCP derivatives TCP and BTCP, and cocaine using a progressive ratio schedule in the rat. Behav Pharmacol 6:223-228
110. Frewer LJ, Lader M (1993). The effects of nefazodone, imipramine and placebo, alone and combined with alcohol, in normal subjects. Int Clin Psychopharmacol 8:13-20
111. Frye CA, Rhodes ME, Rosellini R, Svare B (2002). The nucleus accumbens as a site of action for rewarding properties of testosterone and its 5alpha-reduced metabolites. Pharmacol Biochem Behav 74:119-127
112. Fuchs V, Coper H (1986). The influence of antihistamine compounds on the oral intake of different addictive drugs. Drug Alcohol Depend 17: 359-364
113. Funderburk FR, Griffiths RR, McLeod DR, Bigelow GE, Mackenzie A, Liebson IA, Nemeth-Coslett R (1988). Relative abuse liability of lorazepam and diazepam: An evaluation in 'recreational' drug users. Drug Alcohol Depend 22: 215-222
114. Gauvin DV, Carl KL, Briscoe RJ, Vallett M, Holloway FA (1995). Crossgeneralization between a cocaine cue and two antihistamines. Eur J Pharmacol 294:281-288
115. Gavend MR, Serre-Debeauvais F, Gavend M (1986). The role of serotonin in the behavioral changes induced in the rat by cyclazocine. J Pharmacol 17:601-614
116. Gianutsos G, Lal H (1975). Effect of loperamide, haloperidol and methadone in rats trained to discriminate morphine from saline. Psychopharmacologia 41:267-270
117. Giarola A, Auber A, Chiamulera C (2011). Acetylcholinesterase inhibitors partially generalize to nicotine discriminative stimulus effect in rats. Behav Pharmacol 22:1-6
118. Glennon RA, Young R (1984). MDA: A psychoactive agent with dual stimulus effects. Life Sci 34:379-383
119. Glick SD, Cox RS (1975). Self-Administration of haloperidol in rats. Life Sci 16:1041-1045
120. Glick SD, Guido RA (1982). Scopolamine self-Administration: Cholinergic involvement in reward mechanisms. Life Sci 31:909-913
121. Gold LH, Balster RL (1996). Evaluation of the cocaine-Like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berl) 126:286-292
122. Gosnell BA, Yracheta JM, Bell SM, Lane KE (1996). Intravenous selfadministration of cathinone by rats. Behav Pharmacol 7:526-531
123. Gotestam KG (1973). Intragastric self-Administration of medazepam in rats. Psychopharmacologia 28:87-94
124. Gotestam KG, Andersson BE (1975). Self-Administration of amphetamine analogues in rats. Pharmacol Biochem Behav 3:229-233
125. Grant KA, Samson HH (1985). Oral self administration of ethanol in free feeding rats. Alcohol 2:317-321
126. Green-Jordan K, Grant KA (2000). Modulation of the ethanol-Like discriminative stimulus effects of diazepam and phencyclidine by L-Type voltage-gated calcium-channel ligands in rats. Psychopharmacology (Berl) 149:84-92
127. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 55:463-508
128. Griffin WC 3rd, Nguyen SA, Deleon CP, Middaugh LD (2012). Effects of vigabatrin, an irreversible GABA transaminase inhibitor, on ethanol reinforcement and ethanol discriminative stimuli in mice. Behav Pharmacol 23:178-190
129. Griffith JD, Carranza J, Griffith C, Miller LL (1983). Bupropion: Clinical assay for amphetamine-Like abuse potential. J Clin Psychiatry 44:206-208
130. Griffiths RR, Bigelow GE, Ator NA (2003). Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend 70: S41-S54
131. Grignaschi G, Neill JC, Petrini A, Garattini S, Samanin R (1992). Feeding pattern studies suggest that D-fenfluramine and sertraline specifically enhance the state of satiety in rats. Eur J Pharmacol 211:137-142
132. Gyertyan I, Saghy K, Laszy J, Elekes O, Kedves R, Gemesi LI, et al. (2008). Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-Like activity in rodent models: II. behavioural characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol 378:529-539
133. Harland RD, Gauvin DV, Michaelis RC, Carney JM, Seale TW, Holloway FA (1989). Behavioral interaction between cocaine and caffeine: A drug discrimination analysis in rats. Pharmacol Biochem Behav 32:1017-1023
134. Hashimoto K (2009). Sigma-1 receptors and selective serotonin reuptake inhibitors: Clinical implications of their relationship. Cent Nerv Syst Agents Med Chem 9:197-204
135. Heal DJ, Frankland AT, Gosden J, Hutchins LJ, Prow MR, Luscombe GP, Buckett WR (1992). A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: Evidence that dopamine is not a pharmacological target for sibutramine. Psychopharmacology (Berl) 107:303-309
136. Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC (1998). Sibutramine: A novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from D-Amphetamine and D-fenfluramine. Int J Obes Relat Metab Disord 22 (Suppl 1):S18-S28, discussion S29
137. Health-Canada (2007). Clinical assessment of abuse liability for drugs with central nervous system activity. Available at: Http://www.hc-sc.gc.ca/ dhpmps/ alt-formats/hpfb-Dgpsa/pdf/prodpharma/abuse-liability-abusif-usage- clin-eng.pdf. [Accessed 14 June 2013
138. Heil SH, Holmes HW, Bickel WK, Higgins ST, Badger GJ, Laws HF, Faries DE (2002). Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 67:149-156
139. Heinonen EH, Lammintausta R (1991). A review of the pharmacology of selegiline. Acta Neurol Scand Suppl 136:44-59
140. Heishman SJ, Henningfield JE (1991). Discriminative stimulus effects of d-Amphetamine, methylphenidate, and diazepam in humans. Psychopharmacology (Berl) 103:436-442
141. Henningfield JE, Miyasato K, Jasinski DR (1985). Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther 234:1-12
142. Henningfield JE, Cohen C, Heishman SJ (1991). Drug self-Administration methods in abuse liability evaluation. Br J Addict 86:1571-1577
143. Higgins GA, Wang Y, Sellers EM (1993). Preliminary findings with the indirect 5-HT agonist dexfenfluramine on heroin discrimination and self-Administration in rats. Pharmacol Biochem Behav 45:963-966
144. Hiranita T, Soto PL, Newman AH, Katz JL (2009). Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-Administration in rats: Comparisons with monoamine uptake inhibitors. J Pharmacol Exp Ther 329:677-686
145. Hiranita T, Soto PL, Tanda G, Katz JL (2011). Lack of cocaine-Like discriminativestimulus effects of sigma-receptor agonists in rats. Behav Pharmacol 22:525-530
146. Hoffman DC, Wise RA (1992). Locomotor-Activating effects of the D2 agonist bromocriptine show environment-specific sensitization following repeated injections. Psychopharmacology (Berl) 107:277-284
147. Holman RB (1994). Biological effects of central nervous system stimulants. Addiction 89:1435-1441
148. Holtzman SG (1974). Effects of nalorphine on avoidance behavior and locomotor activity in the rat. Arch Int Pharmacodyn Ther 212:199-204
149. Huang D, Wilson MC (1986). Comparative discriminative stimulus properties of dl-cathinone, D-Amphetamine, and cocaine in rats. Pharmacol Biochem Behav 24:205-210
150. ICH-M3-(R2) (2009). ICH guideline M3 (R2): Guidance on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. Available at: Http://www.ich.org/fileadmin/ Public-Web- Site/ICH-Products/Guidelines/Multidisciplinary/M3-R2/Step4/ M3-R2--Guideline.pdf. [Accessed 14 June 2013].
151. Iorio LC, Ryan EA, Gogerty JH (1976). Combinations of selected CNS depressants with D-Amphetamine or mazindol on food intake and motor activity of rats. Eur J Pharmacol 36:89-94
152. Jaffe AB, Sharpe LG, Jaffe JH (1989). Rats self-Administer sufentanil in aerosol form. Psychopharmacology (Berl) 99:289-293
153. Jaffe JH, Jaffe FK (1989). Historical perspectives on the use of subjective effects measures in assessing the abuse potential of drugs. NIDA Res Monogr 92:43-72
154. Janicak PG, Rado JT (2011). Quetiapine monotherapy for bipolar depression. Expert Opin Pharmacother 12:1643-1651
155. Jarbe TU, Henriksson BG (1974). Discriminative response control produced with hashish, tetrahydrocannabinols (delta 8-THC and delta 9-THC), and other drugs. Psychopharmacologia 40:1-16
156. Jasinski DR, Martin WR, Haertzen CA (1967). The human pharmacology and abuse potential of N-Allylnoroxymorphone (naloxone). J Pharmacol Exp Ther 157:420-426
157. Jasinski DR, Henningfield JE (1989). Human abuse liability assessment by measurement of subjective and physiological effects. NIDA Res Monogr 92:73-100
158. Jasinski DR (2000). An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 14:53-60
159. Johanson CE, de Wit H (1989). The use of choice procedures for assessing the reinforcing properties of drugs in humans. NIDA Res Monogr 92: 171-210
160. Johnson AM (1989). An overview of the animal pharmacology of paroxetine. Acta Psychiatr Scand Suppl 350:14-20
161. Johnson BA, Roache JD, Ait-Daoud N, Wallace C, Wells L, Dawes M, Wang Y (2005). Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on D-methamphetamine's subjective and reinforcing effects. Int J Neuropsychopharmacol 8:203-213
162. Jonas JM, Coleman BS, Sheridan AQ, Kalinske RW (1992). Comparative clinical profiles of triazolam versus other shorter-Acting hypnotics. J Clin Psychiatry 53 (Suppl):19-31, Discussion 32-13
163. Jonsson CO, Sjoberg L (1967). Studies in the psychological effects of a new drug (diethylpropion). Time curves for five subjective variables. Scand J Psychol 8:39-46
164. Jun JH, Thorndike EB, Schindler CW (2004). Abuse liability and stimulant properties of dextromethorphan and diphenhydramine combinations in rats. Psychopharmacology (Berl) 172:277-282
165. Kalix P (1980). Hypermotility of the amphetamine type induced by a constituent of khat leaves. Br J Pharmacol 68:11-13
166. Kaplan HL, Busto UE, Baylon GJ, Cheung SW, Otton SV, Somer G, Sellers EM (1997). Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J Pharmacol Exp Ther 281:103-108
167. Karmarkar SW, Bottum KM, Tischkau SA (2010). Considerations for the use of anesthetics in neurotoxicity studies. Comp Med 60:256-262
168. Katz JL, Goldberg SR (1988). Preclinical assessment of abuse liability of drugs. Agents Actions 23:18-26
169. Katz JL (1990). Models of relative reinforcing efficacy of drugs and their predictive utility. Behav Pharmacol 1:283-301
170. Keating GM, Lyseng-Williamson KA (2005). Tolcapone: A review of its use in the management of Parkinson's disease. CNS Drugs 19:165-184
171. Kelly JP (2011). Cathinone derivatives: A review of their chemistry, pharmacology and toxicology. Drug Test Anal 3:439-453
172. Kim EJ, Park EK, Suh KH (2005). Safety pharmacology of sibutramine mesylate, an anti-obesity drug. Hum Exp Toxicol 24:109-119
173. Kim HS,Wan X, Mathers DA, Puil E (2004). Selective GABA-receptor actions of amobarbital on thalamic neurons. Br J Pharmacol 143:485-494
174. Kim I, Barnes AJ, Oyler JM, Schepers R, Joseph RE Jr, Cone EJ, et al. (2002). Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. Clin Chem 48:1486-1496
175. Kinney JL (1985). Nomifensine maleate: A new second-generation antidepressant. Clin Pharm 4:625-636
176. Kleinrok Z, Ksiazek A, Przesmycki K, Kolasa K (1975). The central action of intraventricularly (ivc) administered propranolol and phentolamine in rat. Pol J Pharmacol Pharm405-412
177. Kobayashi S, Endou M, Sakuraya F, Matsuda N, Zhang XH, Azuma M, et al. (2003). The sympathomimetic actions of L-ephedrine and D-pseudoephedrine: Direct receptor activation or norepinephrine release? Anesth Analg 97:1239-1245
178. Kollins SH (2007). Abuse liability of medications used to treat attention-Deficit/ hyperactivity disorder (ADHD). Am J Addict 16 (Suppl 1):35-42, quiz 43-34
179. Koob GF (1992). Neural mechanisms of drug reinforcement. Ann N Y Acad Sci 654:171-191
180. Kosten TA, Miserendino MJ, Haile CN, DeCaprio JL, Jatlow PI, Nestler EJ (1997). Acquisition and maintenance of intravenous cocaine self-Administration in Lewis and Fischer inbred rat strains. Brain Res 778:418-429
181. Kovacic P, Somanathan R (2009). Novel, unifying mechanism for mescaline in the central nervous system: Electrochemistry, catechol redox metabolite, receptor, cell signaling and structure activity relationships. Oxid Med Cell Longev 2:181-190
182. Kovacs GL, de Wied D (1978). Effects of amphetamine and haloperidol on avoidance behavior and exploratory activity. Eur J Pharmacol 53:103-107
183. Kreek MJ (2000). Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci 909:186-216
184. Krimmer EC, Barry H 3rd, Alvin JD (1982). Discriminative, disinhibitory, and depressant effects of several anticonvulsants. Psychopharmacology (Berl) 78:28-32
185. Kueh D, Baker LE (2007). Reinforcement schedule effects in rats trained to discriminate 3,4-methylenedioxymethamphetamine (MDMA) or cocaine. Psychopharmacology (Berl) 189:447-457
186. Kukanich B, Clark TP (2012). The history and pharmacology of fentanyl: Relevance to a novel, long-Acting transdermal fentanyl solution newly approved for use in dogs. J Vet Pharmacol Ther 35 (Suppl 2):3-19
187. Kumor KM, Haertzen CA, Johnson RE, Kocher T, Jasinski D (1986). Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J Pharmacol Exp Ther 238:960-968
188. Kwan P, Brodie MJ (2004). Phenobarbital for the treatment of epilepsy in the 21st century: A critical review. Epilepsia 45:1141-1149
189. Lamb RJ, Griffiths RR (1990). Self-Administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine. Psychopharmacology (Berl) 102:183-190
190. Lambadjieva ND (1999). Influence of testosterone on some behavioral reactions of male immature rats exposed to continual light. Methods Find Exp Clin Pharmacol 21:17-20
191. Lange KW (1998). Clinical pharmacology of dopamine agonists in Parkinson's disease. Drugs Aging 13:381-389
192. Lange WR, Jasinski DR (1986). The clinical pharmacology of pentazocine and tripelennamine (T's and Blues). Adv Alcohol Subst Abuse 5:71-83
193. Lee F, Stafford I, Hoebel BG (1989). Similarities between the stimulus properties of phenylpropanolamine and amphetamine. Psychopharmacology (Berl) 97:410-412
194. Lemberg KK, Kontinen VK, Siiskonen AO, Viljakka KM, Yli-Kauhaluoma JT, Korpi ER, Kalso EA (2006). Antinociception by spinal and systemic oxycodone: Why does the route make a difference? In vitro and in vivo studies in rats. Anesthesiology 105:801-812
195. Leonard BE, McCartan D,White J, King DJ (2004). Methylphenidate: A review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 19:151-180
196. Leri F, Burns LH (2005). Ultra-Low-Dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats. Pharmacol Biochem Behav 82:252-262
197. LeSage MG, Stafford D, Glowa JR (2000). Abuse liability of the anesthetic propofol: Self-Administration of propofol in rats under fixed-ratio schedules of drug delivery. Psychopharmacology (Berl) 153:148-154
198. Leviel V (2011). Dopamine release mediated by the dopamine transporter, facts and consequences. J Neurochem 118:475-489
199. Levin ED, Bushnell PJ, Rezvani AH (2011). Attention-modulating effects of cognitive enhancers. Pharmacol Biochem Behav 99:146-154
200. Lew EO, Richardson JS (1981). Neurochemical and behavioural correlates of the interaction between amphetamine and delta 9-Tetrahydrocannabinol in the rat. Drug Alcohol Depend 8:93-101
201. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA (1988). Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661-670
202. Lieberman AN, Goldstein M (1985). Bromocriptine in Parkinson disease. Pharmacol Rev 37:217-227
203. Lile JA, Kelly TH, Hays LR (2012). Separate and combined effects of the GABA reuptake inhibitor tiagabine and delta9-THC in humans discriminating Delta9-THC. Drug Alcohol Depend 122:61-69
204. Liu HJ, Sato K, Shih HC, Shibuya T, Kawamoto H, Kitagawa H (1985). Pharmacologic studies of the central action of zopiclone: Effects on locomotor activity and brain monoamines in rats. Int J Clin Pharmacol Ther Toxicol121-128
205. Lobina C, Agabio R, Reali R, Gessa GL, Colombo G (1999). Contribution of GABA(A) and GABA(B) receptors to the discriminative stimulus produced by gamma-hydroxybutyric acid. Pharmacol Biochem Behav 64:363-365
206. Lucki I, Ward HR, Frazer A (1989). Effect of 1-(m-chlorophenyl)piperazine and 1-(m-Trifluoromethylphenyl)piperazine on locomotor activity. J Pharmacol Exp Ther 249:155-164
207. Lukas SE, Mendelson JH, Benedikt R (1995). Electroencephalographic correlates of marihuana-induced euphoria. Drug Alcohol Depend 37: 131-140
208. Lynch JJ 3rd, Castagne V, Moser PC, Mittelstadt SW (2011). Comparison of methods for the assessment of locomotor activity in rodent safety pharmacology studies. J Pharmacol Toxicol Methods 64:74-80
209. Madden C, Singer G, Oei TP (1979). The involvement of interoceptive factors in the maintenance of heroin-seeking behavior. Pharmacol Biochem Behav 11:445-448
210. Madras BK, Xie Z, Lin Z, Jassen A, Panas H, Lynch L, et al. (2006). Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 319:561-569
211. Mailman RB, Murthy V (2010). Third generation antipsychotic drugs: Partial agonism or receptor functional selectivity? Curr Pharm Des 16:488-501
212. Maj J, Rogoz Z, Skuza G, Sowinska H, Superata J (1990). Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease. J Neural Transm Park Dis Dement Sect 2:101-112
213. Markert LE, Roberts DC (1991). 3,4-Methylenedioxyamphetamine (MDA) self-Administration and neurotoxicity. Pharmacol Biochem Behav 39: 569-574
214. Marquis KL, Moreton JE (1987). Animal models of intravenous phencyclinoid selfAdministration. Pharmacol Biochem Behav 27:385-389
215. Marshall FH, Stratton SC, Mullings J, Ford E,Worton SP, Oakley NR, Hagan RM (1997). Development of tolerance in mice to the sedative effects of the neuroactive steroid minaxolone following chronic exposure. Pharmacol Biochem Behav 58:1-8
216. Martone CH, Nagelhout J, Wolf SM (1991). Methohexital: A practical review for outpatient dental anesthesia. Anesth Prog 38:195-199
217. Maurel S, Schreiber R, De Vry J (1997). Substitution of the selective serotonin reuptake inhibitors fluoxetine and paroxetine for the discriminative stimulus effects of ethanol in rats. Psychopharmacology (Berl) 130:404-406
218. Maurice T, Meunier J, Feng B, Ieni J, Monaghan DT (2006). Interaction with sigma(1) protein, but not N-methyl-D-Aspartate receptor, is involved in the pharmacological activity of donepezil. J Pharmacol Exp Ther 317: 606-614
219. McColl SL, Burstein AH, Reeves KR, Billing CB Jr., Stolar M, Sellers EM (2008). Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers. Clin Pharmacol Ther 83:607-614
220. McGivney WT, McMillan DE (1979). The effects of acetylmethadol on motor activity and schedule-controlled responding. Pharmacol Biochem Behav 10:261-265
221. Meert TF, de Haes P, Janssen PA (1989). Risperidone (R 64 766), a potent and complete LSD antagonist in drug discrimination by rats. Psychopharmacology (Berl) 97:206-212
222. Meliska CJ, Trevor AJ (1978). Differential effects of ketamine on schedulecontrolled responding and motility. Pharmacol Biochem Behav 8:679-683
223. Mello NK, Mendelson JH, Sholar MB, Jaszyna-Gasior M, Goletiani N, Siegel AJ (2005). Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men. Neuropsychopharmacology 30:618-632
224. Miksic S, Shearman G, Lal H (1978). Generalization study with some narcotic and nonnarcotic drugs in rats trained for morphine-saline discrimination. Psychopharmacology (Berl) 60:103-104
225. Mintzer MZ, Guarino J, Kirk T, Roache JD, Griffiths RR (1997). Ethanol and pentobarbital: Comparison of behavioral and subjective effects in sedative drug abusers. Exp Clin Psychopharmacol 5:203-215
226. Minzenberg MJ, Carter CS (2008). Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology 33:1477-1502
227. Mittleman G, Rushing PA, Winders SE (1993). Effects of phenylpropanolamine on regulatory and nonregulatory ingestion in adult rats. Physiol Behav 54:515-521
228. Moolten MS, Fishman JB, Chen JC, Carlson KR (1993). Etonitazene: An opioid selective for the mu receptor types. Life Sci 52:PL199-PL203
229. Moran-Gates T, Zhang K, Baldessarini RJ, Tarazi FI (2005). Atomoxetine blocks motor hyperactivity in neonatal 6-hydroxydopamine-Lesioned rats: Implications for treatment of attention-Deficit hyperactivity disorder. Int J Neuropsychopharmacol 8:439-444
230. Mumford G, Silverman K, Griffiths RR (1996). Reinforcing, subjective, and performance effects of lorazepam and diphenhydramine in humans. Exp Clin Psychopharmacol 4:421-430
231. Myhrer T, Enger S, Aas P (2010). Behavioral side effects in rats treated with acetylcholinesterase inhibitors suggested used as prophylactics against nerve agents. Pharmacol Biochem Behav 95:338-343
232. Naranjo C, Shulgin AT, Sargent T (1967). Evaluation of 3,4-methylenedioxyamphetamine (MDA) as an adjunct to psychotherapy. Med Pharmacol Exp Int J Exp Med 17:359-364
233. Nehlig A, Daval JL, Debry G (1992). Caffeine and the central nervous system: Mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev 17:139-170
234. Neil MJ (2011). Clonidine: Clinical pharmacology and therapeutic use in pain management. Curr Clin Pharmacol 6:280-287
235. Nelson DL, Gehlert DR (2006). Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine 29: 49-60
236. Newman JL, Vann RE, May EL, Beardsley PM (2002). Heroin discriminative stimulus effects of methadone, LAAM and other isomers of acetylmethadol in rats. Psychopharmacology (Berl) 164:108-114
237. Nicholson KL, Hayes BA, Balster RL (1999). Evaluation of the reinforcing properties and phencyclidine-Like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys. Psychopharmacology (Berl) 146:49-59
238. Nielsen EB, Jepsen SA (1985). Antagonism of the amphetamine cue by both classical and atypical antipsychotic drugs. Eur J Pharmacol 111: 167-176
239. Nielsen JA, Duda NJ, Mokler DJ, Moore KE (1984). Self-Administration of central stimulants by rats: A comparison of the effects of d-Amphetamine, methylphenidate and McNeil 4612. Pharmacol Biochem Behav 20: 227-232
240. Nierenberg J, Ator NA (1990). Drug discrimination in rats successively trained to discriminate diazepam and pentobarbital. Pharmacol Biochem Behav 35:405-412
241. NIH (2011). Topics in brief (2011): Prescription drug abuse. Available at: Http:// www.drugabuse.gov/sites/default/files/prescription-1.pdf. [Accessed 14 June 2013
242. Nishida N, Hasegawa Y, Chiba S,Wakimasu M, Fujino M (1989a). Discriminative stimulus effects of enkephalin analogs, EK-209 and EK-399, in rats. Eur J Pharmacol 174:71-76
243. Nishida N, Hasegawa Y, Chiba S, Wakimasu M, Fujino M (1989b). Reinforcing effects of the enkephalin analogs, EK-209 and EK-399, in rats. Eur J Pharmacol 166:453-458
244. Nisoli E, Carruba MO (2000). An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev 1:127-139
245. O'Connor EC, Mead AN (2010). Tramadol acts as a weak reinforcer in the rat self-Administration model, consistent with its low abuse liability in humans. Pharmacol Biochem Behav 96:279-286
246. O'Connor EC, Chapman K, Butler P, Mead AN (2011). The predictive validity of the rat self-Administration model for abuse liability. Neurosci Biobehav Rev 35:912-938
247. Ohmori S, Morimoto Y (2002). Dihydroetorphine: A potent analgesic: Pharmacology, toxicology, pharmacokinetics, and clinical effects. CNS Drug Rev 8:391-404
248. Oka T, Hosoya K (1976). The effect of p-chlorophenylalanine on the pethidine-or methadone-induced decrease in locomotor activity of rats. Eur J Pharmacol 37:393-395
249. Okun MS, Boothby LA, Bartfield RB, Doering PL (2001). GHB: An important pharmacologic and clinical update. J Pharm Pharm Sci 4:167-175
250. ONDCP (2013). Prescription Drug Abuse In: Office of National Drug Control Policy
251. Overton DA, Shen CF, Ke GY, Gazdick LP (1989). Discriminable effects of phencyclidine analogs evaluated by multiple drug (PCP versus OTHER) discrimination training. Psychopharmacology (Berl) 97:514-520
252. Pain L, Jeltsch H, Lehmann O, Lazarus C, Laalou FZ, Cassel JC (2000). Central cholinergic depletion induced by 192 IgG-saporin alleviates the sedative effects of propofol in rats. Br J Anaesth 85:869-873
253. Palenicek T, Balikova M, Bubenikova-Valesova V, Horacek J (2008). Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose. Psychopharmacology (Berl) 196:51-62
254. Palumbo PA,Winter JC (1994). Interactions of clozapine with the stimulus effects of DOM and LSD. Pharmacol Biochem Behav 49:115-120
255. Panlilio LV, Schindler CW (2000). Self-Administration of remifentanil, an ultrashort acting opioid, under continuous and progressive-ratio schedules of reinforcement in rats. Psychopharmacology (Berl) 150:61-66
256. Papasava M, Singer G, Papasava CL (1985). Phentermine self-Administration in naive free-feeding and food-Deprived rats: A dose response study. Psychopharmacology (Berl) 85:410-413
257. Paterson NE, Fedolak A, Olivier B, Hanania T, Ghavami A, Caldarone B (2010). Psychostimulant-Like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents. Pharmacol Biochem Behav 95:449-456
258. Paul D, Pick CG, Tive LA, Pasternak GW (1991). Pharmacological characterization of nalorphine, a kappa 3 analgesic. J Pharmacol Exp Ther 257:1-7
259. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. (2010). International Union of Basic and Clinical Pharmacology. LXXIX Cannabinoid receptors and their ligands: Beyond CB(1) and CB(2). Pharmacol Rev 62:588-631
260. Pilotto R, Singer G, Overstreet D (1984). Self-injection of diazepam in naive rats: Effects of dose, schedule and blockade of different receptors. Psychopharmacology (Berl) 84:174-177
261. Porsolt RD, Pawelec C, Roux S, Jalfre M (1984). Discrimination of the amphetamine cue. Effects of A, B and mixed type inhibitors of monoamine oxidase. Neuropharmacology 23:569-573
262. Preston KL, Sullivan JT, Strain EC, Bigelow GE (1992). Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. J Pharmacol Exp Ther 262:279-291
263. Pulvirenti L, Koob GF (1994). Dopamine receptor agonists, partial agonists and psychostimulant addiction. Trends Pharmacol Sci 15:374-379
264. Ren YH, Zheng JW (2000). Influence of tramadol on morphine discriminative behavior in rats. Acta Pharmacol Sin 21:924-926
265. Ribaric S (2012). The pharmacological properties and therapeutic use of apomorphine. Molecules 17:5289-5309
266. Richardson JS (1970). The self-injection of amobarbital by rats during nonreward. Int J Addict 5:739-746
267. Richardson NR, Roberts DC (1996). Progressive ratio schedules in drug selfadministration studies in rats: A method to evaluate reinforcing efficacy. J Neurosci Methods1-11
268. Richelson E (2001). Pharmacology of antidepressants. Mayo Clin Proc 76: 511-527
269. Riley J, Eisenberg E, Muller-Schwefe G, Drewes AM, Arendt-Nielsen L (2008). Oxycodone: A review of its use in the management of pain. Curr Med Res Opin 24:175-192
270. Roberts DC, Bennett SA (1993). Heroin self-Administration in rats under a progressive ratio schedule of reinforcement. Psychopharmacology (Berl) 111:215-218
271. Rocha BA, Ward AS, Egilmez Y, Lytle DA, Emmett-Oglesby MW (1996). Tolerance to the discriminative stimulus and reinforcing effects of ketamine. Behav Pharmacol 7:160-168
272. Rogoz Z, Dziedzicka-Wasylewska M, Maj J (1998). Pharmacological profile of venlafaxine, a new antidepressant, given acutely. Pol J Pharmacol 50: 107-115
273. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, et al. (2007). Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52:985-994
274. Rowlett JK,Woolverton WL (1997). Discriminative stimulus effects of zolpidem in pentobarbital-Trained subjects: I. Comparison with triazolam in rhesus monkeys and rats. J Pharmacol Exp Ther 280:162-173
275. Rowlett JK (2000). A labor-supply analysis of cocaine self-Administration under progressive-ratio schedules: Antecedents, methodologies, and perspectives. Psychopharmacology (Berl) 153:1-16
276. Rowley HL, Butler SA, Prow MR, Dykes SG, Aspley S, Kilpatrick IC, Heal DJ (2000). Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats. Synapse 38:167-176
277. Rumore MM, Schlichting DA (1985). Analgesic effects of antihistaminics. Life Sci 36:403-416
278. Sagratella S (1995). NMDA antagonists: Antiepileptic-neuroprotective drugs with diversified neuropharmacological profiles. Pharmacol Res 32:1-13
279. Sahakian BJ, Robbins TW, Morgan MJ, Iversen SD (1975). The effects of psychomotor stimulants on stereotypy and locomotor activity in sociallydeprived and control rats. Brain Res 84:195-205
280. Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, et al. (2003). Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305:1024-1036
281. Sansone M (1980). Influence of benzodiazepine tranquilizers on scopolamineinduced locomotor stimulation in mice. Psychopharmacology (Berl) 71: 243-245
282. Sansone M, Castellano C, D'Amato FR (1986). Enhancement of morphineinduced hyperactivity by antihistaminic drugs in mice. Arch Int Pharmacodyn Ther 284 (Issue 2):239-245
283. Schechter MD, Cook PG (1975). Dopaminergic mediation of the interoceptive cue produced by D-Amphetamine in rats. Psychopharmacologia 42:185-193
284. Schechter MD, Rosecrans JA (1973). D-Amphetamine as a discriminative cue: Drugs with similar stimulus properties. Eur J Pharmacol 21:212-216
285. Schenk S, Gittings D, Johnstone M, Daniela E (2003). Development, maintenance and temporal pattern of self-Administration maintained by ecstasy (MDMA) in rats. Psychopharmacology (Berl) 169:21-27
286. Schenk S, Hely L, Lake B, Daniela E, Gittings D, Mash DC (2007). MDMA selfadministration in rats: Acquisition, progressive ratio responding and serotonin transporter binding. Eur J Neurosci 26:3229-3236
287. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, et al. (1997). Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83-97
288. Schuh LM, Schuster CR, Hopper JA, Mendel CM (2000). Abuse liability assessment of sibutramine, a novel weight control agent. Psychopharmacology (Berl) 147:339-346
289. Schuster CR, Johanson CE (1988). Relationship between the discriminative stimulus properties and subjective effects of drugs. Psychopharmacol Ser 4:161-175
290. Seeman P (2002). Atypical antipsychotics: Mechanism of action. Can J Psychiatry 47:27-38
291. Shannon HE, Holtzman SG (1976). Evaluation of the discriminative effects of morphine in the rat. J Pharmacol Exp Ther 198:54-65
292. Shannon HE, Holtzman SG (1977). Further evaluation of the discriminative effects of morphine in the rat. J Pharmacol Exp Ther 201:55-66
293. Shannon HE, Herling S (1983). Discriminative stimulus effects of diazepam in rats: Evidence for a maximal effect. J Pharmacol Exp Ther 227:160-166
294. Shearman GT, Hynes M, Lal H (1981). Self-Administration of clonidine by the rat. Prog Clin Biol Res 71:259-276
295. Shelton KL, Balster RL (1994). Ethanol drug discrimination in rats: Substitution with GABA agonists and NMDA antagonists. Behav Pharmacol 5:441-451
296. Shimazoe T, Shibata S, Ueki S (1987). A new forced swimming test for the evaluation of antidepressants in rats by recording vibration of a water tank. J Pharmacobiodyn 10:639-643
297. Shortall SE, Macerola AE, Swaby RT, Jayson R, Korsah C, Pillidge KE, et al. (2012). Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. Eur Neuropsychopharmacol [Epub ahead of print
298. Shram MJ, Sellers EM, Romach MK (2011). Oral ketamine as a positive control in human abuse potential studies. Drug Alcohol Depend 114:185-193
299. Simon P, Hemet C, Costentin J (1996). Analysis of stimulant locomotor effects of modafinil in various strains of mice and rats. Fundam Clin Pharmacol 431-435
300. Smith JW, Mogg A, Tafi E, Peacey E, Pullar IA, Szekeres P, Tricklebank M (2007). Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. Psychopharmacology (Berl) 190:157-170
301. Smith MC, Riskin BJ (1991). The clinical use of barbiturates in neurological disorders. Drugs 42:365-378
302. Spyraki C, Fibiger HC (1981). Intravenous self-Administration of nomifensine in rats: Implications for abuse potential in humans. Science 212:1167-1168
303. Stahl SM, Grady MM, Moret C, Briley M (2005). SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 10:732-747
304. Steinfels GF, Young GA, Khazan N (1982). Self-Administration of nalbuphine, butorphanol and pentazocine by morphine post-Addict rats. Pharmacol Biochem Behav 16:167-171
305. Stephens DN, Duka T, Crombag HS, Cunningham CL, Heilig M, Crabbe JC (2010). Reward sensitivity: Issues of measurement, and achieving consilience between human and animal phenotypes. Addict Biol 15:145-168
306. Stirling JM, Cross AJ, Green AR (1989). The binding of [3H]thienyl cyclohexylpiperidine ([3H]TCP) to the NMDA-phencyclidine receptor complex. Neuropharmacology 28:1-7
307. Stroumpos C, Manolaraki M, Paspatis GA (2010). Remifentanil, a different opioid: Potential clinical applications and safety aspects. Expert Opin Drug Saf 9:355-364
308. Suzdak PD, Jansen JA (1995). A review of the preclinical pharmacology of tiagabine: A potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 36:612-626
309. Suzuki T, Mori T, Tsuji M, Misawa M, Onodera K (1997). Interactions between H1-Antagonists and opioids: A drug discrimination study. Psychopharmacology (Berl) 131:346-353
310. Swerdlow NR, Koob GF (1985). Separate neural substrates of the locomotoractivating properties of amphetamine, heroin, caffeine and corticotropin releasing factor (CRF) in the rat. Pharmacol Biochem Behav 23:303-307
311. Taeuber K, Zapf R, Rupp W, Badian M (1979). Pharmacodynamic comparison of the acute effects of nomifensine, amphetamine and placebo in healthy volunteers. Int J Clin Pharmacol Biopharm 17:32-37
312. Takada K (1982). Discriminative stimulus effects of pentobarbital in rats. Yakubutsu Seishin Kodo 2:47-55
313. Takahama K, Shirasaki T (2007). Central and peripheral mechanisms of narcotic antitussives: Codeine-sensitive and-resistant coughs. Cough 3:8
314. Takahashi RN, Singer G (1979). Self-Administration of delta 9-Tetrahydrocannabinol by rats. Pharmacol Biochem Behav 11:737-740
315. Tanda G, Kopajtic TA, Katz JL (2008). Cocaine-Like neurochemical effects of antihistaminic medications. J Neurochem 106:147-157
316. Tella SR, Ladenheim B, Cadet JL (1997). Differential regulation of dopamine transporter after chronic self-Administration of bupropion and nomifensine. J Pharmacol Exp Ther 281:508-513
317. Terry P,Witkin JM, Katz JL (1994). Pharmacological characterization of the novel discriminative stimulus effects of a low dose of cocaine. J Pharmacol Exp Ther 270:1041-1048
318. Tokuyama S, Takahashi M, Kaneto H (1993). Antinociceptive effect of dihydroetorphine and its tolerance/dependence liability in mice. Biol Pharm Bull 16:774-777
319. Tomkins DM, Otton SV, Joharchi N, Li NY, Balster RF, Tyndale RF, Sellers EM (1997). Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J Pharmacol Exp Ther 280:1374-1382
320. Trescot AM, Datta S, Lee M, Hansen H (2008). Opioid pharmacology. Pain Physician 11:S133-S153
321. Trugman JM, James CL, Wooten GF (1991). D1/D2 dopamine receptor stimulation by L-Dopa. A [14C]-2-Deoxyglucose autoradiographic study. Brain 114 (Pt 3):1429-1440
322. Tunnicliff G (1997). Sites of action of gamma-hydroxybutyrate (GHB)-A neuroactive drug with abuse potential. J Toxicol Clin Toxicol 35:581-590
323. Tyndale RF, Bhave SV, Hoffmann E, Hoffmann PL, Tabakoff B, Tobin AJ, Olsen RW (1997). Pentobarbital decreases the gamma-Aminobutyric acidA receptor subunit gamma-2 long/short mRNA ratio by a mechanism distinct from receptor occupation. J Pharmacol Exp Ther 283:350-357
324. Tzschentke TM, Bruckmann W, Friderichs E (2002). Lack of sensitization during place conditioning in rats is consistent with the low abuse potential of tramadol. Neurosci Lett 329:25-28
325. USDHH (2011). Substance abuse and mental health services Administration. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration
326. Van Nieuwenhuijzen PS, McGregor IS (2009). Sedative and hypothermic effects of gamma-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: Assessment using biotelemetry. Drug Alcohol Depend 103:137-147
327. Vartanian MG, Radulovic LL, Kinsora JJ, Serpa KA, Vergnes M, Bertram E, Taylor CP (2006). Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res 68:189-205
328. Wachtel SR, Ortengren A, de Wit H (2002). The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug Alcohol Depend 68:23-33
329. Waddington JL (1978). Behavioural evidence for GABAergic activity of the benzodiazepine flurazepam. Eur J Pharmacol 51:417-422
330. Walker DJ, Zacny JP (1999). Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers. J Pharmacol Exp Ther 289:1454-1464
331. Walker EA, Richardson TM, Young AM (1997). Tolerance and cross-Tolerance to morphine-Like stimulus effects of mu opioids in rats. Psychopharmacology (Berl) 133:17-28
332. Walsh SL, Strain EC, Abreu ME, Bigelow GE (2001). Enadoline, a selective kappa opioid agonist: Comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) 157:151-162
333. Watanabe Y, Saito H, Abe K (1993). Tricyclic antidepressants block NMDA receptor-mediated synaptic responses and induction of long-Term potentiation in rat hippocampal slices. Neuropharmacology 32:479-486
334. Wellman PJ, Shelton K, Schenk S (1989). Self-Administration of phenylpropanolamine (PPA) by rats previously trained to self-Administer amphetamine. Pharmacol Biochem Behav 34:187-191
335. Werner TE, Smith SG, Davis WM (1976). A dose-response comparison between methadone and morphine self-Administration. Psychopharmacologia 47: 209-211
336. Wiley JL, Lowe JA, Balster RL, Martin BR (1995a). Antagonism of the discriminative stimulus effects of delta 9-Tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther 275:1-6
337. Wiley JL, Barrett RL, Lowe J, Balster RL, Martin BR (1995b). Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 34:669-676
338. Wilkinson CJ (1998). The abuse potential of zolpidem administered alone and with alcohol. Pharmacol Biochem Behav 60:193-202
339. Willetts J, Balster RL (1988). The discriminative stimulus effects of N-methyl-Daspartate antagonists in phencyclidine-Trained rats. Neuropharmacology 27:1249-1256
340. Winter JC, Helsley S, Fiorella D, Rabin RA (1999). The acute effects of monoamine reuptake inhibitors on the stimulus effects of hallucinogens. Pharmacol Biochem Behav 63:507-513
341. Winter JC, Rice KC, Amorosi DJ, Rabin RA (2007). Psilocybin-induced stimulus control in the rat. Pharmacol Biochem Behav 87:472-480
342. Wirkner K, Eberts C, Poelchen W, Allgaier C, Illes P (2000). Mechanism of inhibition by ethanol of NMDA and AMPA receptor channel functions in cultured rat cortical neurons. Naunyn Schmiedebergs Arch Pharmacol 362:568-576
343. Wise RA, Murray A, Bozarth MA (1990). Bromocriptine self-Administration and bromocriptine-reinstatement of cocaine-Trained and heroin-Trained lever pressing in rats. Psychopharmacology (Berl) 100:355-360
344. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM (2001). Dopaminergic role in stimulant-induced wakefulness. J Neurosci 21:1787-1794
345. Witkin JM, Nichols DE, Terry P, Katz JL (1991). Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections. J Pharmacol Exp Ther 257:706-713
346. Wonnacott S, Sidhpura N, Balfour DJ (2005). Nicotine: From molecular mechanisms to behaviour. Curr Opin Pharmacol 5:53-59
347. Wood DM, Lal H, Yaden S, Emmett-Oglesby MW (1985). One-way generalization of clonidine to the discriminative stimulus produced by cocaine. Pharmacol Biochem Behav 23:529-533
348. Wood DM, Emmette-Oglesby MW (1988). Substitution and cross-Tolerance profiles of anorectic drugs in rats trained to detect the discriminative stimulus properties of cocaine. Psychopharmacology (Berl) 95:364-368
349. Wood RI, Johnson LR, Chu L, Schad C, Self DW (2004). Testosterone reinforcement: Intravenous and intracerebroventricular self-Administration in male rats and hamsters. Psychopharmacology (Berl) 171:298-305
350. Wooters TE, Bardo MT (2007). The monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of nicotine in rats. Behav Pharmacol 18:601-608
351. Wu WR, Zheng JW, Li FY, Li Y (1998). Immunosuppressive effects of intravenous self administration of dihydroetorphine on lymphocyte functions in rats. Zhongguo Yao Li Xue Bao 19:387-390
352. Yen M, Ewald MB (2012). Toxicity of weight loss agents. J Med Toxicol 8:145-152
353. Yokel RA, Pickens R (1973). Self-Administration of optical isomers of amphetamine and methylamphetamine by rats. J Pharmacol Exp Ther 187:27-33
354. Yokel RA, Wise RA (1978). Amphetamine-Type reinforcement by dopaminergic agonists in the rat. Psychopharmacology (Berl) 58:289-296
355. Yoshimura K, Horiuchi M, Inoue Y, Yamamoto K (1984). Pharmacological studies on drug dependence. (III): Intravenous self-Administration of some CNSaffecting drugs and a new sleep-inducer, 1H-1, 2, 4-Triazolyl benzophenone derivative (450191-S), in rats. Nihon Yakurigaku Zasshi 83:39-67
356. Young GA, Steinfels GF, Khazan N (1979). Spontaneous vs. naloxone-induced abstinence in dependent rats self-Administering L-Alpha-Acetylmethadol (LAAM) or morphine. Pharmacol Biochem Behav 10:585-589
357. Young R, Glennon RA, Brase DA, Dewey WL (1986). Potencies of diazepam metabolites in rats trained to discriminate diazepam. Life Sci 39:17-20
358. Young R, Gabryszuk M, Glennon RA (1998). (-)Ephedrine and caffeine mutually potentiate one another's amphetamine-Like stimulus effects. Pharmacol Biochem Behav 61:169-173
359. Zacny JP (2005). Profiling the subjective, psychomotor, and physiological effects of tramadol in recreational drug users. Drug Alcohol Depend 80:273-278
360. Zacny JP, Gutierrez S (2003). Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-Drug-Abusing volunteers. Psychopharmacology (Berl) 170:242-254
361. Zacny JP, Goldman RE (2004). Characterizing the subjective, psychomotor, and physiological effects of oral propoxyphene in non-Drug-Abusing volunteers. Drug Alcohol Depend 73:133-140
362. Zacny JP, Lichtor JL, Zaragoza JG, Coalson DW, Uitvlugt AM, Flemming DC, et al. (1993). Assessing the behavioral effects and abuse potential of propofol bolus injections in healthy volunteers. Drug Alcohol Depend 32:45-57
363. Zacny JP, Hill JL, Black ML, Sadeghi P (1998). Comparing the subjective, psychomotor and physiological effects of intravenous pentazocine and morphine in normal volunteers. J Pharmacol Exp Ther 286:1197-1207
364. Zacny JP, Paice JA, Coalson DW (2012). Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. Pharmacol Biochem Behav 100:560-565
365. Zakusov VV, Ostrovskaya RU, Kozhechkin SN, Markovich VV, Molodavkin GM, Voronina TA (1977). Further evidence for GABA-ergic mechanisms in the action of benzodiazepines. Arch Int Pharmacodyn Ther 229: 313-326
366. Zaniewska M, McCreary AC, Stefanski R, Przegalinski E, Filip M (2008). Effect of varenicline on the acute and repeated locomotor responses to nicotine in rats. Synapse 62:935-939
367. Zarnowska ED, Mozrzymas JW (2001). Differential effects of chlorpromazine on ionotropic glutamate receptors in cultured rat hippocampal neurons. Neurosci Lett 305:53-56
368. Zarrindast MR (1981). Dopamine-Like properties of ephedrine in rat brain. Br J Pharmacol 74:119-122
369. Zawertailo LA, Busto U, Kaplan HL, Sellers EM (1995). Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans. J Clin Psychopharmacol 15:117-124
370. Zawertailo LA, Busto UE, Kaplan HL, Greenblatt DJ, Sellers EM (2003). Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. J Clin Psychopharmacol 23:269-280
371. Zawertailo LA, Tyndale RF, Busto U, Sellers EM(2010). Effect of metabolic blockade on the psychoactive effects of dextromethorphan. Hum Psychopharmacol 25:71-79
372. Zebrowska-Lupina I, Kozyrska C, Stelmasiak M (1980). Interaction between antidepressants and alpha-Adrenergic receptor blocking agents. Pol J Pharmacol Pharm 32:673-680
373. Zhu CZ, Mills CD, Hsieh GC, Zhong C, Mikusa J, Lewis LG, et al. (2012). Assessing carrageenan-induced locomotor activity impairment in rats: Comparison with evoked endpoint of acute inflammatory pain. Eur J Pain 16:816-826